Iron-dependent ferroptosis in cardiac microvascular endothelial cells: a key link between dysregulated iron homeostasis and microcirculatory injury during myocardial ischemia-reperfusion - Report - MDSpire

Iron-dependent ferroptosis in cardiac microvascular endothelial cells: a key link between dysregulated iron homeostasis and microcirculatory injury during myocardial ischemia-reperfusion

  • By

  • Xiaoya Li

  • Qingbo Shi

  • Zhiqiang Wang

  • Zhiwen Zhang

  • Muwei Li

  • May 7, 2026

  • 0 min

Share

Clinical Report: Ferroptosis in Cardiac Microvascular Endothelial Cells

Overview

Revise to include specific examples of how ferroptosis contributes to microcirculatory damage.

Background

Myocardial ischemia-reperfusion (I/R) injury is a significant clinical challenge following procedures like percutaneous coronary intervention. Despite successful restoration of blood flow, microvascular dysfunction can lead to persistent tissue damage and poor outcomes. Understanding the mechanisms underlying this dysfunction, particularly the role of ferroptosis in CMECs, is essential for developing targeted therapies.

Data Highlights

No specific numerical data provided in the source material.

Key Findings

Rephrase findings for clarity and ensure they are directly supported by the source.

Clinical Implications

Clinicians should consider the role of iron dysregulation and ferroptosis in managing myocardial I/R injury. Targeted therapies aimed at preserving endothelial function may enhance microvascular reperfusion and improve patient outcomes post-PCI.

Conclusion

Ferroptosis represents a critical mechanism linking iron dysregulation to microvascular injury in myocardial I/R. Addressing this pathway may offer new therapeutic avenues to enhance myocardial salvage and patient recovery.

Related Resources & Content

  1. Frontiers in Immunology, 2026 -- Ferroptosis-immune crosstalk in CNS diseases: mechanisms and translational insights
  2. Archives of Toxicology, 2023 -- Regulation of Ferroptosis via Nrf2 and Its Role in Neurodegenerative Disorders
  3. Frontiers in Immunology, 2026 -- Ferroptosis: a promising therapeutic target for periodontitis
  4. Infection, 2021 -- Excess Cardiac Iron Levels Contribute to Heart Damage in Severe COVID-19 Patients
  5. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes
  6. STRIVE: Alteplase Does Not Improve Microvascular Obstruction, MACE in Patients Undergoing Primary PCI - American College of Cardiology
  7. Phase-dependent iron dysmetabolism in myocardial ischemia-reperfusion injury: From mechanisms to therapies - ScienceDirect
  8. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
  9. STRIVE: Alteplase Does Not Improve Microvascular Obstruction, MACE in Patients Undergoing Primary PCI - American College of Cardiology
  10. Phase-dependent iron dysmetabolism in myocardial ischemia-reperfusion injury: From mechanisms to therapies - ScienceDirect

Original Source(s)

Iron-dependent ferroptosis in cardiac microvascular endothelial cells: a key link between dysregulated iron homeostasis and microcirculatory injury during myocardial ischemia-reperfusion

  • by Xiaoya Li, Qingbo Shi, Zhiqiang Wang, Zhiwen Zhang, Muwei Li

  • May 7, 2026

Related Content

Case Study: An Emerging Etiology for ST-Segment Elevation in Lead aVR

Tirofiban After Tenecteplase in Stroke

Adjunctive tirofiban was linked to higher rates of positive 90-day outcomes in acute ischemic stroke.

Masters Athletes Present Unique CV Findings

Joint clinical consensus outlines evaluation and management considerations for arrhythmias, coronary atherosclerosis, aortic dilatation, myocardial fibrosis, and related findings in older competitive athletes.